doxapram has been researched along with Infant, Premature, Diseases in 40 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants." | 9.22 | Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. ( Benard, M; Boutroy, MJ; Casper, C; Greze, E; Haddad, FE; Hamon, I; Hascoët, JM, 2016) |
| "Methylxanthines and doxapram are currently used to treat apnea of prematurity but are not fully effective and often present undesirable side effects." | 9.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "To study the effect of doxapram on the frequency of apnoea, bradycardia and hypoxaemia." | 9.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity." | 9.05 | Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. ( Alpan, G; Arad, I; Dgani, Y; Eyal, F; Glick, B; Peleg, O; Sagi, E, 1985) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, for which caffeine is the first treatment of choice." | 8.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| "Although intravenous Doxapram might reduce apnea within the first 48 hours of treatment, there are insufficient data to evaluate the precision of this result or to assess potential adverse effects." | 8.82 | Doxapram treatment for apnea in preterm infants. ( Henderson-Smart, D; Steer, P, 2004) |
| "Searches were made of the Oxford Database of Perinatal trials, the Cochrane Collaboration Clinical Trials Register, MEDLINE 1966 - July 2001, Embase 1980 - July 2001, CINAHL 1982 - July 2001 (using text words 'doxapram', 'apnea or apnoea' and MeSH term 'infant, premature'), previous reviews including cross references, abstracts, conferences and symposia proceedings, expert informants, mainly in the English language." | 8.81 | Doxapram treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2001) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 8.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 8.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 8.80 | Doxapram treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 8.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)." | 7.83 | Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016) |
| "0 mg/kg per h in combination with methylxanthines and the frequency of apnea and secondary outcomes were compared with a group of control infants." | 7.71 | Low-dose doxapram therapy for idiopathic apnea of prematurity. ( Fujimura, M; Itahashi, K; Kajiwara, M; Yamazaki, T, 2001) |
| "Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment." | 7.70 | [Treatment of apnea in prematurity]. ( Boutroy, MJ; Hascoët, JM, 1998) |
| "We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects." | 7.68 | Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991) |
| "The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea." | 7.68 | Doxapram for the initial treatment of idiopathic apnea of prematurity. ( Bairam, A; Faulon, M; Monin, P; Vert, P, 1992) |
| "Eighteen infants with idiopathic apnea of prematurity refractory to therapeutic levels of aminophylline were treated with incremental doses of doxapram beginning at 0." | 7.67 | Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, G, 1987) |
| "Pharmacokinetics of doxapram were determined in 13 infants with idiopathic apnea of prematurity uncontrolled by aminophylline and caffeine." | 7.67 | Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ( Beaudry, MA; Bradley, JM; Gramlich, LM; LeGatt, D, 1988) |
| "Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2." | 7.67 | Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986) |
| " Other pharmacokinetic indices, although variable, did not exhibit binomial distribution." | 5.27 | Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, GA, 1988) |
| "Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants." | 5.22 | Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. ( Benard, M; Boutroy, MJ; Casper, C; Greze, E; Haddad, FE; Hamon, I; Hascoët, JM, 2016) |
| "Doxapram is used to treat apnea of prematurity when there is an insufficient response to methylxanthine treatment." | 5.11 | Effect of doxapram on cerebral blood flow velocity in preterm infants. ( Horsch, S; Roll, C, 2004) |
| "Methylxanthines and doxapram are currently used to treat apnea of prematurity but are not fully effective and often present undesirable side effects." | 5.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "To study the effect of doxapram on the frequency of apnoea, bradycardia and hypoxaemia." | 5.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity." | 5.05 | Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. ( Alpan, G; Arad, I; Dgani, Y; Eyal, F; Glick, B; Peleg, O; Sagi, E, 1985) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, for which caffeine is the first treatment of choice." | 4.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| "Although intravenous Doxapram might reduce apnea within the first 48 hours of treatment, there are insufficient data to evaluate the precision of this result or to assess potential adverse effects." | 4.82 | Doxapram treatment for apnea in preterm infants. ( Henderson-Smart, D; Steer, P, 2004) |
| "Searches were made of the Oxford Database of Perinatal trials, the Cochrane Collaboration Clinical Trials Register, MEDLINE 1966 - July 2001, Embase 1980 - July 2001, CINAHL 1982 - July 2001 (using text words 'doxapram', 'apnea or apnoea' and MeSH term 'infant, premature'), previous reviews including cross references, abstracts, conferences and symposia proceedings, expert informants, mainly in the English language." | 4.81 | Doxapram treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2001) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 4.80 | Doxapram treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 4.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 4.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Recurrent apnea is common in preterm infants, particularly at very early gestational ages." | 4.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity can persist despite caffeine therapy in preterm infants." | 4.02 | The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Koch, BCP; Poets, CF; Reiss, IKM; Simons, SHP; Völler, S, 2021) |
| "Doxapram is a treatment option for severe apnea of prematurity (AOP)." | 3.91 | Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. ( de Jongh, FH; de Waal, CG; Hutten, GJ; Kraaijenga, JV; van Kaam, AH, 2019) |
| "Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)." | 3.83 | Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016) |
| "Doxapram is a respiratory stimulant widely used for the treatment of idiopathic apnea of prematurity, although it has been demonstrated that it can induce a transient decrease of cerebral blood flow and that isolated mental delay in infants weighing <1,250 g is associated with the total dosage and duration of doxapram therapy." | 3.73 | Brain hemodynamic effects of doxapram in preterm infants. ( Bertini, G; Dani, C; Filippi, L; Pezzati, M; Pratesi, S; Rubaltelli, FF; Tronchin, M, 2006) |
| "0 mg/kg per h in combination with methylxanthines and the frequency of apnea and secondary outcomes were compared with a group of control infants." | 3.71 | Low-dose doxapram therapy for idiopathic apnea of prematurity. ( Fujimura, M; Itahashi, K; Kajiwara, M; Yamazaki, T, 2001) |
| "Doxapram, a respiratory stimulant, is used to treat idiopathic apnea of prematurity." | 3.70 | Second-degree atrioventricular heart block after doxapram administration. ( De Villiers, GS; Kalis, NN; Van der Merwe, PL; Walele, A, 1998) |
| "Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment." | 3.70 | [Treatment of apnea in prematurity]. ( Boutroy, MJ; Hascoët, JM, 1998) |
| "The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea." | 3.68 | Doxapram for the initial treatment of idiopathic apnea of prematurity. ( Bairam, A; Faulon, M; Monin, P; Vert, P, 1992) |
| "We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects." | 3.68 | Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991) |
| "Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2." | 3.67 | Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986) |
| "Eighteen infants with idiopathic apnea of prematurity refractory to therapeutic levels of aminophylline were treated with incremental doses of doxapram beginning at 0." | 3.67 | Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, G, 1987) |
| "Pharmacokinetics of doxapram were determined in 13 infants with idiopathic apnea of prematurity uncontrolled by aminophylline and caffeine." | 3.67 | Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ( Beaudry, MA; Bradley, JM; Gramlich, LM; LeGatt, D, 1988) |
| "Doxapram treatment influences aEEG in preterm infants, showing higher percentages of continuous activity as well as more electrographic seizure activity and less sleep-wake cycling." | 1.40 | Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants. ( Berger, A; Czaba-Hnizdo, C; Klebermass-Schrehof, K; Olischar, M; Rona, Z; Weninger, M, 2014) |
| "Doxapram-treated infants were significantly younger and had a lower birth weight." | 1.39 | Doxapram and hypokalaemia in very preterm infants. ( Ferdynus, C; Fischer, C; Gouyon, JB; Semama, DS, 2013) |
| "Doxapram infusion was given to five preterm infants in whom therapeutic concentrations of theophylline had failed to control episodes of apnoea." | 1.27 | Idiopathic apnoea of prematurity treated with doxapram and aminophylline. ( Alpan, G; Arad, I; Eyal, F; Patz, D; Sagi, E, 1984) |
| " Other pharmacokinetic indices, although variable, did not exhibit binomial distribution." | 1.27 | Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, GA, 1988) |
| "Doxapram was detected by mass spectrometry for blood and plasma assays, and by flame ionisation for urine assays." | 1.26 | Quantitation of doxapram in blood, plasma and urine. ( Moore, RG; Nichol, H; Thomas, J; Vine, J, 1980) |
| " At the moment, xanthines are the drugs of choice, since they are both effective and safe, provided dosage is adjusted to each patient." | 1.26 | [Drug treatment of apnoea in premature infants (author's transl)]. ( Klethi, J; Mack, G; Messer, J; Willard, D, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (35.00) | 18.7374 |
| 1990's | 7 (17.50) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 6 (15.00) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Borenstein-Levin, L | 1 |
| Poppe, JA | 2 |
| van Weteringen, W | 2 |
| Taal, HR | 1 |
| Hochwald, O | 1 |
| Kugelman, A | 1 |
| Reiss, IKM | 3 |
| Simons, SHP | 3 |
| Völler, S | 2 |
| Willemsen, SP | 1 |
| Goos, TG | 1 |
| Engbers, AGJ | 1 |
| Poets, CF | 2 |
| Knibbe, CAJ | 1 |
| Koch, BCP | 1 |
| Flint, RB | 1 |
| de Waal, CG | 1 |
| Hutten, GJ | 1 |
| Kraaijenga, JV | 1 |
| de Jongh, FH | 1 |
| van Kaam, AH | 3 |
| Fischer, C | 1 |
| Ferdynus, C | 1 |
| Gouyon, JB | 1 |
| Semama, DS | 1 |
| Czaba-Hnizdo, C | 1 |
| Olischar, M | 1 |
| Rona, Z | 1 |
| Weninger, M | 1 |
| Berger, A | 1 |
| Klebermass-Schrehof, K | 1 |
| Ten Hove, CH | 2 |
| Vliegenthart, RJ | 2 |
| Te Pas, AB | 1 |
| Brouwer, E | 1 |
| Rijken, M | 1 |
| van Wassenaer-Leemhuis, AG | 1 |
| Onland, W | 2 |
| Greze, E | 1 |
| Benard, M | 1 |
| Hamon, I | 1 |
| Casper, C | 1 |
| Haddad, FE | 1 |
| Boutroy, MJ | 2 |
| Hascoët, JM | 2 |
| Roll, C | 1 |
| Horsch, S | 1 |
| Henderson-Smart, D | 1 |
| Steer, P | 3 |
| Marlier, L | 1 |
| Gaugler, C | 1 |
| Messer, J | 2 |
| Dani, C | 1 |
| Bertini, G | 1 |
| Pezzati, M | 1 |
| Pratesi, S | 1 |
| Filippi, L | 1 |
| Tronchin, M | 1 |
| Rubaltelli, FF | 1 |
| Willard, D | 1 |
| Mack, G | 1 |
| Klethi, J | 1 |
| Sagi, E | 3 |
| Eyal, F | 3 |
| Alpan, G | 3 |
| Patz, D | 2 |
| Arad, I | 2 |
| Springer, C | 1 |
| Goder, K | 1 |
| Nichol, H | 1 |
| Vine, J | 1 |
| Thomas, J | 1 |
| Moore, RG | 1 |
| De Villiers, GS | 1 |
| Walele, A | 1 |
| Van der Merwe, PL | 1 |
| Kalis, NN | 1 |
| Darraj, S | 1 |
| Bohnhorst, B | 1 |
| Henderson-Smart, DJ | 4 |
| Steer, PA | 2 |
| Bhatia, J | 1 |
| Yamazaki, T | 1 |
| Kajiwara, M | 1 |
| Itahashi, K | 1 |
| Fujimura, M | 1 |
| Finer, NN | 4 |
| Barrington, KJ | 4 |
| Hayes, BJ | 1 |
| Hugh, A | 1 |
| Bairam, A | 2 |
| Faulon, M | 1 |
| Monin, P | 1 |
| Vert, P | 2 |
| Ruggins, NR | 1 |
| Tay-Uyboco, J | 1 |
| Kwiatkowski, K | 1 |
| Cates, DB | 1 |
| Seifert, B | 1 |
| Hasan, SU | 1 |
| Rigatto, H | 1 |
| Peters, KL | 1 |
| Barton, J | 1 |
| Torok-Both, G | 1 |
| Jamali, F | 2 |
| Coutts, RT | 2 |
| Torok-Both, GA | 1 |
| Beaudry, MA | 1 |
| Bradley, JM | 1 |
| Gramlich, LM | 1 |
| LeGatt, D | 1 |
| Rose, SJ | 1 |
| Lloyd, DJ | 1 |
| Duffty, P | 1 |
| Hayakawa, F | 1 |
| Hakamada, S | 1 |
| Kuno, K | 1 |
| Nakashima, T | 1 |
| Miyachi, Y | 1 |
| Cater, G | 1 |
| Shaffer, S | 1 |
| Hall, RT | 1 |
| Jordan, GD | 1 |
| Themelis, NJ | 1 |
| Messerly, SO | 1 |
| Jarrett, RV | 1 |
| Garcia, J | 1 |
| Frank, CG | 1 |
| Glick, B | 1 |
| Peleg, O | 1 |
| Dgani, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants[NCT00389909] | Phase 4 | 85 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for doxapram and Infant, Premature, Diseases
| Article | Year |
|---|---|
Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
Topics: Apnea; Caffeine; Doxapram; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infa | 2017 |
Doxapram treatment for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2004 |
Doxapram treatment for apnea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respirator | 2000 |
Doxapram versus methylxanthine for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2000 |
Current options in the management of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Prema | 2000 |
Doxapram versus methylxanthine for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2000 |
Doxapram treatment for apnea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respirator | 2001 |
Pathophysiology of apnoea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Larynx; Pharynx; Positive-Pre | 1991 |
6 trials available for doxapram and Infant, Premature, Diseases
| Article | Year |
|---|---|
Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial.
Topics: Apnea; Double-Blind Method; Doxapram; Female; Humans; Infant; Infant, Newborn; Infant, Premature; In | 2016 |
Effect of doxapram on cerebral blood flow velocity in preterm infants.
Topics: Anterior Cerebral Artery; Apnea; Blood Flow Velocity; Cerebrovascular Circulation; Doxapram; Female; | 2004 |
Olfactory stimulation prevents apnea in premature newborns.
Topics: Apnea; Aromatherapy; Bradycardia; Caffeine; Central Nervous System Stimulants; Combined Modality The | 2005 |
Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants.
Topics: Apnea; Birth Weight; Bradycardia; Caffeine; Doxapram; Drug Resistance; Gestational Age; Humans; Hypo | 1999 |
Obstructive, mixed, and central apnea in the neonate: physiologic correlates.
Topics: Analysis of Variance; Doxapram; Drug Therapy, Combination; Heart Rate; Humans; Infant, Newborn; Infa | 1992 |
Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study.
Topics: Aminophylline; Apnea; Double-Blind Method; Doxapram; Drug Resistance; Drug Therapy, Combination; Hum | 1985 |
26 other studies available for doxapram and Infant, Premature, Diseases
| Article | Year |
|---|---|
Oxygen saturation histogram classification system to evaluate response to doxapram treatment in preterm infants.
Topics: Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Oxygen; O | 2023 |
Use of Continuous Physiological Monitor Data to Evaluate Doxapram Therapy in Preterm Infants.
Topics: Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Oxygen; R | 2020 |
The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age.
Topics: Apnea; Caffeine; Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2021 |
Doxapram Treatment and Diaphragmatic Activity in Preterm Infants.
Topics: Apnea; Birth Weight; Diaphragm; Doxapram; Electromyography; Female; Gestational Age; Humans; Infant, | 2019 |
Doxapram and hypokalaemia in very preterm infants.
Topics: Analysis of Variance; Apnea; Diuretics; Doxapram; Female; Furosemide; Humans; Hypokalemia; Infant, E | 2013 |
Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants.
Topics: Apnea; Brain; Doxapram; Electroencephalography; Female; Gestational Age; Humans; Infant, Newborn; In | 2014 |
Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Central Nervous System Stimulants; Child Development; Doxapram; D | 2016 |
Brain hemodynamic effects of doxapram in preterm infants.
Topics: Apnea; Birth Weight; Blood Flow Velocity; Brain; Case-Control Studies; Doxapram; Gestational Age; Hu | 2006 |
[Drug treatment of apnoea in premature infants (author's transl)].
Topics: Apnea; Chemoreceptor Cells; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Neurotra | 1981 |
Idiopathic apnoea of prematurity treated with doxapram and aminophylline.
Topics: Aminophylline; Apnea; Carbon Dioxide; Doxapram; Drug Therapy, Combination; Female; Humans; Infant, N | 1984 |
Doxapram in the treatment of idiopathic apnea of prematurity unresponsive to aminophylline.
Topics: Aminophylline; Apnea; Doxapram; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature, Dise | 1984 |
Quantitation of doxapram in blood, plasma and urine.
Topics: Apnea; Doxapram; Flame Ionization; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Infant, | 1980 |
Second-degree atrioventricular heart block after doxapram administration.
Topics: Apnea; Doxapram; Female; Heart Block; Humans; Hyaline Membrane Disease; Infant, Newborn; Infant, Pre | 1998 |
[Treatment of apnea in prematurity].
Topics: Apnea; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infa | 1998 |
Low-dose doxapram therapy for idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature; Infant, Prem | 2001 |
Doxapram for the initial treatment of idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Respiration; To | 1992 |
Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant, Ne | 1991 |
Low-dose doxapram for apnoea of prematurity.
Topics: Apnea; Caffeine; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature, Di | 1986 |
Physiologic effects of doxapram in idiopathic apnea of prematurity.
Topics: Aminophylline; Apnea; Birth Weight; Blood Pressure; Carbon Dioxide; Doxapram; Gestational Age; Human | 1986 |
Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity.
Topics: Apnea; Blood Pressure; Carbon Dioxide; Dose-Response Relationship, Drug; Doxapram; Half-Life; Heart | 1987 |
Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data.
Topics: Apnea; Doxapram; Drug Administration Schedule; Humans; Infant, Newborn; Infant, Premature, Diseases | 1988 |
Pharmacokinetics of doxapram in idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Female; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases | 1988 |
Doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases | 1987 |
Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentrations.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, Parenteral | 1986 |
Doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases | 1986 |
Doxapram and potential benzyl alcohol toxicity: a moratorium on clinical investigation?
Topics: Benzyl Alcohol; Benzyl Alcohols; Benzyl Compounds; Doxapram; Humans; Infant, Newborn; Infant, Premat | 1986 |